We see that in animal models, in immune disease models. There is a — some people have referred to it as the Goldilocks effect or there is an effect here where you have an impact on the differentiation of T-cells. We think that’s best at around 200 milligrams and 400 milligrams, BID. But when you go too high, you get general immunosuppression and that’s probably not a good thing. So the 200 milligram dose looks really good for us both from a efficacy standpoint, mechanism of action, etcetera and then finally, from a safety standpoint, most companies go into FDA and they want to use the highest dose they studied. We’re actually going — we’re actually going to say, no, we don’t want to use our highest dose when we studied. We actually want to use a dose, that’s one third of what we — what we studied.
Roger, does that answer your question?
Roger Song: Absolutely. Really appreciate. That’s very helpful. Thank you. Rich.
Operator: Your next question comes from Li Watsek with Cantor Fitzgerald. Please go ahead.
UnidentifiedAnalyst: Thanks so much for taking our questions. Just a couple of quick ones regarding this 200 milligram cohort; you said that enrolment has accelerated. Do you potentially know why this might be the case? Like could it be given by data you let out or there other factories
Richard Miller: Easy question. Accelerated because of Ash. Okay. People at ASH saw, holy mackerel, this is a really novel mechanism of action. It’s active in refractory patients. Ash, I think it’s really Ash. Now, of course, we made some amendments to the protocol right around that, right before that enrolling on the lymphocyte count, etcetera. But we have a lot more interest in this trial now.
UnidentifiedAnalyst: Got it. Thank you. And then just moving on to the biomarker beyond this 900 cut-off, do you see any correlative data with responses and 900 and above, like any linear correlations? And also, have you potentially seen any validation from the new patients you’ve enrolled with this selective criteria; or is it too early to tell?
Richard Miller: So in terms of having a straight line linear correlation, I don’t think we have enough data to say that and enough responders yet. But, clearly the people who have done the best have had normal. I think one of our CRs got to have a lymphocyte count of 4,000, which is right in the normal range. So we’re getting the suspicion that there might be some relationship there. In terms of the new patients they’re now being selected on the basis of ALC above 900 and stay tuned for that. We’re seeing some real, I think, really interesting things there.
UnidentifiedAnalyst: Great. Thank you so much. It,
Richard Miller: It looks really good now. Just one other question. There are some other biomarkers that we’re interested in and we just don’t have enough data yet, but one of the biomarkers that we are interested in and we’ve talked about before is what’s a transcription factor called GATA3. GATA3 is in Th2 helper T-cells. GATA3 positive tumors are bad. GATA3 positive peripheral T-cell lymphomas are the worst, the worst of the worst. All of our responders are GATA3 positive.
UnidentifiedAnalyst: Okay. Got it. I’ll note that. Thank you so much.
Operator: Our next question comes from Ryan Konik with Titan Partners Group. Please go ahead. Pardon me, Mr. Konik, is your line on mute perhaps?
Richard Miller: Yeah, I think we lost Titan Partners there, but are there any other questions? I don’t see any. Well, I want to thank everyone for participating in our call today and we look forward to updating you on our subsequent quarterly conference calls. Thanks a lot. And take care.
Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.
